The Librexia program evaluating milvexian is unrivaled as the most comprehensive factor XIa inhibitor clinical development program to date and will provide extensive data from nearly 50,000 patients, ...
The FDA has opened up the fast lane for Bayer and Johnson & Johnson's ($JNJ) new blood thinner Xarelto. The drug will get priority review for a third indication ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results